Literature DB >> 10732752

Individuals with presumably hereditary uveal melanoma do not harbour germline mutations in the coding regions of either the P16INK4A, P14ARF or cdk4 genes.

N Soufir1, B Bressac-de Paillerets, L Desjardins, C Lévy, J Bombled, I Gorin, P Schlienger, D Stoppa-Lyonnet.   

Abstract

In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4). Uveal malignant melanoma (UMM) also occurs in a familial setting, or sometimes in association with familial or sporadic CMM. Molecular studies of sporadic UMM have revealed somatic deletions covering the INK4A-ARF locus (encoding P16INK4A and P14ARF) in a large proportion of tumours. We hypothesized that germline mutations in the p16INK4A, p14ARF or CDK4 genes might contribute to some cases of familial UMM, or to some cases of UMM associated with another melanoma. Out of 155 patients treated at the Institut Curie for UMM between 1994 and 1997, and interviewed about their personal and familial history of melanoma, we identified seven patients with a relative affected with UMM (n = 6) or CMM (n = 1), and two patients who have had, in addition to UMM, a personal history of second melanoma, UMM (n = 1), or CMM (n = 1). We screened by polymerase chain reaction single-strand conformation polymorphism the entire coding sequence of the INK4A-ARF locus (exon 1alpha from p16INK4A, exon 1beta from p14ARF, and exons 2 and 3, common to both genes), as well as the exons 2, 5 and 8 of the CDK4 gene, coding for the functional domains involved in p16 and/or cyclin D1 binding. A previously reported polymorphism in exon 3 of the INK4A-ARF locus was found in one patient affected with bilateral UMM, but no germline mutations were detected, either in the p16INK4A, p14ARF or CDK4 genes. Our data support the involvement of other genes in predisposition to uveal melanoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10732752      PMCID: PMC2374387          DOI: 10.1054/bjoc.1999.1005

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  36 in total

1.  Familial uveal melanoma: absence of germline mutations involving the cyclin-dependent kinase-4 inhibitor gene (p16).

Authors:  A D Singh; C M Croce; K K Wary; J A Shields; L A Donoso; C L Shields; K Huebner; M Ohta
Journal:  Ophthalmic Genet       Date:  1996-03       Impact factor: 1.803

Review 2.  CDKN2 mutations in melanoma.

Authors:  N C Dracopoli; J W Fountain
Journal:  Cancer Surv       Date:  1996

3.  Constitutional alterations in p16 in patients with uveal melanoma.

Authors:  X Wang; K M Egan; E S Gragoudas; K T Kelsey
Journal:  Melanoma Res       Date:  1996-12       Impact factor: 3.599

4.  Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma.

Authors:  L Zuo; J Weger; Q Yang; A M Goldstein; M A Tucker; G J Walker; N Hayward; N C Dracopoli
Journal:  Nat Genet       Date:  1996-01       Impact factor: 38.330

5.  Family studies in melanoma: identification of the atypical mole syndrome (AMS) phenotype.

Authors:  J A Newton Bishop; V Bataille; E Pinney; D T Bishop
Journal:  Melanoma Res       Date:  1994-08       Impact factor: 3.599

6.  Chromosomal gains and losses in uveal melanomas detected by comparative genomic hybridization.

Authors:  M R Speicher; G Prescher; S du Manoir; A Jauch; B Horsthemke; N Bornfeld; R Becher; T Cremer
Journal:  Cancer Res       Date:  1994-07-15       Impact factor: 12.701

7.  Chromosome 9p deletions in cutaneous malignant melanoma tumors: the minimal deleted region involves markers outside the p16 (CDKN2) gene.

Authors:  S Puig; A Ruiz; C Lázaro; T Castel; M Lynch; J Palou; A Vilalta; J Weissenbach; J M Mascaro; X Estivill
Journal:  Am J Hum Genet       Date:  1995-08       Impact factor: 11.025

8.  Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.

Authors:  A Kamb; D Shattuck-Eidens; R Eeles; Q Liu; N A Gruis; W Ding; C Hussey; T Tran; Y Miki; J Weaver-Feldhaus
Journal:  Nat Genet       Date:  1994-09       Impact factor: 38.330

9.  Familial uveal melanoma. Clinical observations on 56 patients.

Authors:  A D Singh; C L Shields; P De Potter; J A Shields; B Trock; J Cater; D Pastore
Journal:  Arch Ophthalmol       Date:  1996-04

10.  Familial uveal melanoma, III. Is the occurrence of familial uveal melanoma coincidental?.

Authors:  A D Singh; M X Wang; L A Donoso; C L Shields; P D Potter; J A Shields; R C Elston; B Fijal
Journal:  Arch Ophthalmol       Date:  1996-09
View more
  13 in total

Review 1.  The genetics of uveal melanoma: an emerging framework for targeted therapy.

Authors:  J William Harbour
Journal:  Pigment Cell Melanoma Res       Date:  2012-02-13       Impact factor: 4.693

2.  Deregulation of the Rb and p53 pathways in uveal melanoma.

Authors:  M A Brantley; J W Harbour
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

3.  Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma.

Authors:  B Buecher; M Gauthier-Villars; L Desjardins; L Lumbroso-Le Rouic; C Levy; A De Pauw; J Bombled; C Tirapo; C Houdayer; B Bressac-de Paillerets; D Stoppa-Lyonnet
Journal:  Fam Cancer       Date:  2010-12       Impact factor: 2.375

4.  Cancer family history characterization in an unselected cohort of 121 patients with uveal melanoma.

Authors:  M H Abdel-Rahman; R Pilarski; S Ezzat; J Sexton; F H Davidorf
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

5.  Inactivation of retinoblastoma protein in uveal melanoma by phosphorylation of sites in the COOH-terminal region.

Authors:  M A Brantley; J W Harbour
Journal:  Cancer Res       Date:  2000-08-15       Impact factor: 12.701

6.  Germline BAP1 alterations in familial uveal melanoma.

Authors:  Karan Rai; Robert Pilarski; Getachew Boru; Muneeb Rehman; Ahmad H Saqr; James B Massengill; Arun Singh; Meghan J Marino; Frederick H Davidorf; Colleen M Cebulla; Mohamed H Abdel-Rahman
Journal:  Genes Chromosomes Cancer       Date:  2016-10-26       Impact factor: 5.006

Review 7.  Familial melanoma: a complex disorder leading to controversy on DNA testing.

Authors:  Femke A de Snoo; Wilma Bergman; Nelleke A Gruis
Journal:  Fam Cancer       Date:  2003       Impact factor: 2.375

Review 8.  Genetics of primary intraocular tumors.

Authors:  Nisha Nagarkatti-Gude; Yujuan Wang; Mohammad Javed Ali; Santosh G Honavar; Martine J Jager; Chi-Chao Chan
Journal:  Ocul Immunol Inflamm       Date:  2012-08       Impact factor: 3.070

9.  Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas.

Authors:  S C Edmunds; I A Cree; F Dí Nícolantonío; J L Hungerford; J S Hurren; D P Kelsell
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

Review 10.  Treating cancer with selective CDK4/6 inhibitors.

Authors:  Ben O'Leary; Richard S Finn; Nicholas C Turner
Journal:  Nat Rev Clin Oncol       Date:  2016-03-31       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.